| A continuously updated collection of Hematology and Oncology papers that encapsulate current basic and applied knowledge, provide evidence and analysis that changes current thinking and practice, and/or point to where these fiields are going and how to prepare for and help create that future. | ||
| February 8, 2019 | Abstracts | |
| Promise of Wearable Physical Activity Monitors in Oncology Practice. |Beg MS, et al. J Oncol Pract. 2017 Feb;13(2):82-89. Review. PMID: 28387544 |
PubMed | |
| beg18_wearable-monitors-onc_joncprec-28387544 | ||
| Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Haikala, HM, et al. Nature Communications 2019 10:620 | https://doi.org/10.1038/s41467-019-08541-2 |
PubMed | |
| haikala19_metformin-myc-pd1-iici_natcom | ||
| Best supportive care in clinical trials: review of the inconsistency in control arm design. Nipp RD, et al. Br J Cancer. 2015 Jun 30;113(1):6-11. Epub 2015 Jun 11. Review. PMID: 26068397 |
PubMed | |
| nipp15_bsc-clin-trials-inconsistent_bjccan-26068397 | ||
| T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Ott PA, et al. J Clin Oncol. 2019 Feb 1;37(4):318-327. Epub 2018 Dec 13. PMID: 30557521 |
PubMed | |
| ott19_predict-efficacy-pembro_jco-30557521 | ||
| Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. Scully M,et al; HERCULES Investigators. N Engl J Med. 2019 Jan 24;380(4):335-346. Epub 2019 Jan 9. PMID: 30625070 |
PubMed | |
| scully19_caplacizumab-ttp_nejm-30625070 | ||
| Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Togashi Y, Shitara K, Nishikawa H. Nat Rev Clin Oncol. 2019 Jan 31. [Epub ahead of print] Review. PMID: 30705439 |
PubMed | |
| togashi19_reg-t-ca-immsupp_natrevclinonc-30705439 | ||
| January 2, 2019 | Abstracts | |
| Targeting KRAS Directly. McCormick, F. Annu. Rev Cancer Biol 2018 Mar 2 (1): 81-90 https://www.annualreviews.org/doi/10.1146/annurev-cancerbio-050216-122010 |
PubMed | |
| mccormick18_target-kras_annrevcabio | ||
| Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Paolillo M, Boselli C, Schinelli S. Brain Sci. 2018 Jan 16;8(1). pii: E15. Review. PMID: 29337870 |
PubMed | |
| paolillo18_gbm-uncer-siege-rev_brainsci-29337870 | ||
| Simultaneous multiplexed amplicon sequencing and transcriptome profiling in single cells. Saikia M, et al. Nat Methods. 2019 Jan;16(1):59-62. Epub 2018 Dec 17. PMID: 30559431 |
PubMed | |
| saikia18_dart-seq-rna-pcr_natmeth-30559431 | ||
| Management of Small Bowel Neuroendocrine Tumors. Scott AT, Howe JR. J Oncol Pract. 2018 Aug;14(8):471-482. PMID: 30096273 |
PubMed | |
| scott18_small-bowel-net-rev_joncprac-30096273 | ||
| How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. Steensma DP. Blood. 2018;132(16):1657-1663. [No authors listed] Blood. 2018 Nov 29;132(22):2419. No abstract available. PMID: 30498072 |
PubMed | |
| steensma18_how-use-mol-gen-mds_blood-30498072 | ||
| What FLT3 inhibitor holds the greatest promise? Stone RM. Best Pract Res Clin Haematol. 2018 Dec;31(4):401-404. Epub 2018 Sep 20. Review. PMID: 30466756 |
PubMed | |
| stone18_flt-inhibitor-promise_bprch-30466756 | ||
| December 18, 2018 | Abstracts | |
Non-invasive delivery strategies for biologics. |
PubMed | |
| anselmo18_non-inv-biologic-del_natrevdrugdis-30498202 | ||
| Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. Chua CYX, et al. J Control Release. 2018 Sep 10;285:23-34. Epub 2018 Jul 3. PMID: 30008369 |
PubMed | |
| chua18_local-delivery-mab-breast_jcontrel-30008369 | ||
| A banner year for immunotherapy and targeted therapy. Carlisle JW, Ramalingam SS. Nat Rev Clin Oncol. 2018 Dec 11. [Epub ahead of print] No abstract available. PMID: 30538305 |
PubMed | |
| carlisle18_nsclc-banner-yr-ici_natrevclinonc-30538305 | ||
| Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. Fathi AT, et ak, AG221-C-001 Study Investigators. JAMA Oncol. 2018 Aug 1;4(8):1106-1110. PMID: 29346478 |
PubMed | |
| fathi18_dif-syn-enasidenib_jamaonc-29346478 | ||
| Human Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells that Are Maintained by a Circulating Pool. Fu J, et al. Cell Stem Cell. 2018 Nov 21. pii: S1934-5909(18)30543-5. [Epub ahead of print] PMID: 30503142 |
PubMed | |
| fu18_gi-hem-stem-cells_cellstemcell-30503142 | ||
| Radical shifts in the first-line management of metastatic renal cell carcinoma. Ornstein MC, Rini BI. Nat Rev Clin Oncol. 2018 Dec 11. [Epub ahead of print] No abstract available. PMID: 30538304 |
PubMed | |
| ornstein18_rad-shift-1st-rcc_natrevclinonc-30538304 | ||
| Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. Smith JC, Sheltzer JM. eLife. 2018 Dec 11;7. pii: e39217. PMID: 30526857 |
PubMed | |
| smith18_mut-copynum-alt-ca-prog_elife-30526857 | ||
| December 8, 2018 | Abstracts | |
| New Paradigms and Therapies for Iron Replacement in Iron Deficiency Anemia. Auerbach M. Clin Adv Hematol Oncol. 2018 Nov;16(11):712-715. No abstract available. |
Journal | |
| auerbach18_iron-replacement_clinadvhemonc | ||
| The Role of Deferiprone in Iron Chelation. Hider RC, Hoffbrand AV. N Engl J Med. 2018 Nov 29;379(22):2140-2150. No abstract available. PMID: 30485781 |
PubMed | |
| hider18_iron-overload_nejm-30485781 | ||
| Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study. Ramanathan RK, et al. Clin Cancer Res. 2017 Jul 15;23(14):3638-3648. Epub 2017 Feb 3. PMID: 28159813 |
PubMed | |
| ramanathan17_ferumoxytol-nal-iri-panc_clincares-28159813 | ||
| Mannose impairs tumour growth and enhances chemotherapy. Gonzalez PS, et AL. Nature. 2018 Nov;563(7733):719-723. Epub 2018 Nov 21. PMID: 30464341 |
PubMed | |
| gonzalez18_mannose-ca-growth-chemo_nat-30464341 | ||
| Bispecific antibodies for cancer therapy: A review. Krishnamurthy A, Jimeno A. Pharmacol Ther. 2018 May;185:122-134. Epub 2017 Dec 18. Review. PMID: 29269044 |
PubMed | |
| krishnamurthy18_bispecific-tcell-engager-rev_pharmther-29269044 | ||
| Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. Massarelli E, et al. JAMA Oncol. 2018 Sep 27. [Epub ahead of print] PMID: 30267032 |
PubMed | |
| massarelli18_checkpt-mab-hpv-vac-ca-tx_jamaonc-30267032 | ||
| Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Shah KN, et al. Nat Med. 2018 Nov 26. [Epub ahead of print] PMID: 30478424 |
PubMed | |
| shah18_aurora-kinase-resistance-egfr-nsclc_natmed-30478424 | ||
| November 27, 2018 | Abstracts | |
| Translational target for checkpoint inhibitors. Kingwell K. Nat Rev Immunol. 2018 Nov 19. [Epub ahead of print] No abstract available. PMID: 30451955 |
PubMed | |
| kingwell18_trans-target-pd-l1_natrevimm-30451955 | ||
| Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Cerezo M, et al. Nat Med. 2018 Oct 29. [Epub ahead of print] PMID: 30374200 |
PubMed | |
| cerezo18_trans-escape-elf4f-stat1-pd-l1_natmed-30374200 | ||
| Gastroenteropancreatic Neuroendocrine Tumors. Cives M, Strosberg JR. CA Cancer J Clin. 2018 Nov;68(6):471-487. Epub 2018 Oct 8. Review. PMID: 30295930 |
PubMed | |
| cives18_gipanc-neuroendocrine-ca_cacjc-30295930 | ||
| NTRK fusion-positive cancers and TRK inhibitor therapy. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. Review. PMID: 30333516 |
PubMed | |
| cocco18_ntrk-fusion-trk-inhib_natrevclinonc-30333516 | ||
| Is the overall survival for older adults with AML finally improving? Lancet JE. Best Pract Res Clin Haematol. 2018 Dec;31(4):387-390. Epub 2018 Sep 20. Review. PMID: 30466753 |
PubMed | |
| lancet18_os-older-aml-improve_bestpracrclinhem-30466753 | ||
| Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Paz-Ares L, et al.; KEYNOTE-407 Investigators. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25. PMID: 30280635 |
PubMed | |
| paz-ares18_nsclc-pembro-carbo-tax-sq_nejm-30280635 | ||
| Aplastic Anemia. Young NS. N Engl J Med. 2018 Oct 25;379(17):1643-1656. Review. No abstract available. PMID: 30354958 |
PubMed | |
| young18_aplastic-anemia_nejm-30354958 | ||
| November 18, 2018 | Abstracts | |
| Targeting Toll-Like Receptors for Cancer Therapy. Braunstein MJ, et al. Target Oncol. 2018 Oct;13(5):583-598. PMID: 30229471 |
PubMed | |
| braunstein18_tlr-target-ca-therapy_targonc-30229471 | ||
| Listening to each other: Infectious disease and cancer immunology. Vance RE, et al. Sci Immunol. 2017 Jan 13;2(7). pii: eaai9339. Review. PMID: 28783669 |
PubMed | |
| vance17_listening-id-ca_sci-28783669 | ||
| Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. Dimopoulos MA, et al. N Engl J Med. 2018 Nov 8;379(19):1811-1822. PMID: 30403938 |
PubMed | |
| dimopoulos18_elotuz-poma-dex-mm_nejm-30403938 | ||
| Immunotherapy Combinations in Multiple Myeloma - Known Unknowns. Gormley NJ, Pazdur R. N Engl J Med. 2018 Nov 8;379(19):1791-1795. No abstract available. PMID: 30403935 |
PubMed | |
| gormley18_imm-combo-mm_nejm-30403935 | ||
| Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. Ferrara R, et al. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. PMID: 30193240 |
PubMed | |
| ferrara18_checkpoint-hyperprogression_jamaonc-30193240 | ||
| Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Hayashi Y, et al. Cancer Discov. 2018 Nov;8(11):1438-1457. Epub 2018 Aug 23. PMID: 30139811 |
PubMed | |
| hayashi18_mds-hif1a-central_candis-30139811 | ||
| November 12, 2018 | Abstracts | |
| CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. Advani R, et al. N Engl J Med. 2018 Nov 1;379(18):1711-1721. PMID: 30380386 |
PubMed | |
| advani18_cd47-block-ritux-nhl_nejm-30380386 | ||
| Macrophage Checkpoint Blockade in Cancer - Back to the Future. Mantovani A, Longo DL. N Engl J Med. 2018 Nov 1;379(18):1777-1779. No abstract available. PMID: 30380398 |
PubMed | |
| mantovani18_mac-checkpoint-block-ca_nejm-30380398 | ||
| Haemochromatosis. Brissot P, et al. Nat Rev Dis Primers. 2018 Apr 5;4:18016. Review. PMID: 29620054 |
PubMed | |
| brissot18_hemochrom_natrevdisprim-29620054 | ||
| Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. Camidge DR, et al. N Engl J Med. 2018 Sep 25. [Epub ahead of print] PMID: 30280657 |
PubMed | |
| camidge18_nsclc-brigatinib_nejm-30280657 | ||
| Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. Gresham, G. et al. npj Digital Medicine 1:27, https://doi.org/10.1038/s41746-018-0032-6 |
DOI | |
| gresham18_wearable-monitor-ca_npjdigmed | ||
| Fasting and cancer: molecular mechanisms and clinical application. Nencioni A, Caffa I, Cortellino S, Longo VD. Nat Rev Cancer. 2018 Nov;18(11):707-719. doi: 10.1038/s41568-018-0061-0. Review. PMID: 30327499 |
PubMed | |
| nencioni18_fasting-ca_natrevca-30327499 | ||
| Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Niemeijer AN, et al. Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y. PMID: 30405135 |
PubMed | |
| niemeijer18_pd1-pet_natcom-30405135 | ||
| October 26, 2018 | Abstracts | |
| Leading and Inspiring by Example. [No authors listed] Cell. 2018 Sep 20;175(1):30-33. Epub 2018 Sep 11. PMID: 30217359 |
PubMed | |
| steitz18_leading-inspiring-example_cell-30217359 | ||
| Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Arbour KC, et al. J Clin Oncol. 2018 Oct 1;36(28):2872-2878. Epub 2018 Aug 20. PMID: 30125216 |
PubMed | |
| arbour18_steroids-pd-1-mab_jco-30125216 | ||
| Update on mantle cell lymphoma. Maddocks K. Blood. 2018 Oct 18;132(16):1647-1656. Epub 2018 Aug 28. Review. PMID: 30154113 |
PubMed | |
| maddocks18_update-mantle-cell_blood-30154113 | ||
| Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. Moore K, et al, N Engl J Med. 2018 Oct 21. [Epub ahead of print] PMID: 30345884 |
PubMed | |
| moore18_olaparib-new-ovarian_nejm-30345884 | ||
| Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Schmid P, et al IMpassion130 Trial Investigators. N Engl J Med. 2018 Oct 20. [Epub ahead of print] PMID: 30345906 |
PubMed | |
| schmid18_atez-nab-pac-triple-neg-breast_nejm-30345906 | ||
| Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Sohal DPS, et al. J Clin Oncol. 2018 Aug 20;36(24):2545-2556. Epub 2018 May 23. PMID: 29791286 |
PubMed | |
| sohal18_met-panc-guide-asco_jco-29791286 | ||
| Functional genomic landscape of acute myeloid leukaemia. Tyner JW, et al. Nature. 2018 Oct;562(7728):526-531. Epub 2018 Oct 17. PMID: 30333627 |
PubMed | |
| tyner18_func-gene-landscape-aml_nat-30333627 | ||
| October 15, 2018 | Abstracts | |
| Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Amaria RN, et al. Nat Med. 2018 Oct 8. [Epub ahead of print] PMID: 30297909 |
PubMed | |
| amaria18_neo-nivo-wwo-ipi-mel_natmed-30297909 | ||
| Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Blank CU, et al. Nat Med. 2018 Oct 8. [Epub ahead of print] PMID: 30297911 |
PubMed | |
| blank18_neo-vs-adj-ipi-nivo-mel_natmed-30297911 | ||
| Classification and Personalized Prognosis in Myeloproliferative Neoplasms. Grinfeld J, et al. N Engl J Med. 2018 Oct 11;379(15):1416-1430. PMID: 30304655 |
PubMed | |
| grinfeld18_class-prog-myeloprolif_nejm-30304655 | ||
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. Litton JK, et al. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. PMID: 30110579 |
PubMed | |
| litton18_brca-talazoparib_nejm-30110579 | ||
| A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. Niihara Y, et al. N Engl J Med. 2018 Jul 19;379(3):226-235. PMID: 30021096 |
PubMed | |
| niihara18_l-glut-ss-anemia_nejm-30021096 | ||
| Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Turajlic S, Lancet Oncol. 2017 Aug;18(8):1009-1021. Epub 2017 Jul 7. PMID: 28694034 |
PubMed | |
| turajlic17_indel-ca-neoags_lancetonc-28694034 | ||
| October 11, 2018 | Abstracts | |
| Novel treatment options for anaplastic thyroid cancer. Fallahi P, et al. Expert Rev Endocrinol Metab. 2017 Jul;12(4):279-288. Epub 2017 Jun 15. PMID: 30058884 |
PubMed | |
| fallahi18_novel-rx-anaplastic-thyroid-ca_exprevem-30058884 | ||
| A cell-based model of hemostasis. Hoffman M, Monroe DM 3rd. Thromb Haemost. 2001 Jun;85(6):958-65. Review. PMID: 11434702 |
PubMed | |
| hoffman01_cell-based-model-hemostasis_thromhaem-11434702 | ||
| Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Kurtz DM, et al. J Clin Oncol. 2018 Oct 1;36(28):2845-2853. Epub 2018 Aug 20. PMID: 30125215 |
PubMed | |
| kurtz18_ctdna-outcome-predict-dlbcl_jco-30125215 | ||
| Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. Scher HI, et al. JAMA Oncol. 2018 Sep 1;4(9):1179-1186. PMID: 29955787 |
PubMed | |
| scher18_prostca-ar-v7-biomarker_jamaonc-29955787 | ||
| Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Sekine K, et al. Lung Cancer. 2018 Oct;124:179-188. Epub 2018 Aug 13. PMID: 30268458 |
PubMed | |
| sekine18_lymph-mono-pd1-nsclc_lungca-30268458 | ||
| Biophysical technologies for understanding circulating tumor cell biology and metastasis. Su DW, Nieva J. Transl Lung Cancer Res. 2017 Aug;6(4):473-485. Review. PMID: 28904890 |
PubMed | |
| su17_technol-ctc-biol-met_tlcr-28904890 | ||
| October 5, 2018 | Abstracts | |
| Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies. Barnard ME, et al. JAMA Oncol. 2018 Oct 4. [Epub ahead of print] PMID: 30286239 |
PubMed | |
| barnard18_low-dose-asa-ovarian_jamaonc-30286239 | ||
| Targeting the Residual Leukemia Cells after Chemotherapy. Vu LP, Kharas MG. Cancer Cell. 2018 Sep 10;34(3):353-355. PMID: 30205040 |
PubMed | |
| vu18_target-resid-leuk-cells_cacell-30205040 | ||
| Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Boyd AL, et al. Cancer Cell. 2018 Sep 10;34(3):483-498.e5. PMID: 30205048 |
PubMed | |
| boyd18_chemo-induced-aml-vuln_cacell-30205048 | ||
| Testicular cancer Cheng L, et al. Nature Reviews Disease Primers,| Article citation ID: (2018) 4:29 |
DOI | |
| cheng18_testicular-ca_natrevdisprim | ||
| Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. Hampel H, et al. JAMA Oncol. 2018 Jun 1;4(6):806-813. PMID: 29596542 |
PubMed | |
| hampel18_colorect-lynch-seq-vs_jamaonc-29596542 | ||
| First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Horn L, et al. N Engl J Med. 2018 Sep 25. [Epub ahead of print] PMID: 30280641 |
PubMed | |
| horn18_1st-atez-chemo-sclca_nejm-30280641 | ||
| Accelerating anticancer drug development - opportunities and trade-offs. Nass SJ, et al. Nat Rev Clin Oncol. 2018 Oct 1. [Epub ahead of print] Review. PMID: 30275514 |
PubMed | |
| nass18_acc-anti-ca-drug-dev_natrevclinonc-30275514 | ||
| October 1, 2018 | Abstracts | |
| Natural killer cells and other innate lymphoid cells in cancer. Chiossone L, et al. Nat Rev Immunol. 2018 Sep 12. Review. PMID: 30209347 |
PubMed | |
| chiossone18_nk-cells-innate-ca_natrevimm-30209347 | ||
| Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Gopalakrishnan V, et al. Science. 2018 Jan 5;359(6371):97-103. Epub 2017 Nov 2. PMID: 29097493 |
PubMed | |
| gopalakrishnan18_microbiome-pd1-mel_sci-29097493 (see also Aug30: Routy, et al) | ||
| Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. Laribi K, Alani M, Truong C, Baugier de Materre A. Oncologist. 2018 Sep;23(9):1039-1053. Epub 2018 Apr 19. Review. PMID: 29674443 |
PubMed | |
| laribi18_recent-adv-periph-tcell-lymph_theonc-29674443 | ||
| Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Lenzo NP, et al. Diagnostics (Basel). 2018 Feb 11;8(1). pii: E16. Review. PMID: 29439481 |
PubMed | |
| lenzo18_pca-ga-psma-pet-rev_diag-29439481 | ||
| Venetoclax: A new wave in hematooncology. Mihalyova J, et al. Exp Hematol. 2018 May;61:10-25. Epub 2018 Mar 2. Review. PMID: 29477371 |
PubMed | |
| mihalyova18_venetoclax-new-wave_exphem-29477371 | ||
| A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R, et al. Lancet Oncol. 2018 Sep;19(9):1180-1191. Epub 2018 Aug 14. PMID: 30120041 |
PubMed | |
| sun18_radiomics-pd1-biomarker_lancetonc-30120041 | ||
| September 17, 2018 | Abstracts | |
| Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma Auslander N, et al. Nat Med. 2018 Aug 20. [Epub ahead of print] PMID: 30127394 |
PubMed | |
| auslander18_mel-predict-mab-response_natmed-30127394 | ||
| IL-23 secreted by myeloid cells drives castration-resistant prostate cancer Calcinotto A, et al. Nature. 2018 Jul;559(7714):363-369. Epub 2018 Jun 27. PMID: 29950727 |
PubMed | |
| calcinotto18_il-23-mdsc-crpc_nat-29950727 | ||
| Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience Glassman DC, et al. BMC Cancer. 2018 Jun 27;18(1):693. PMID: 29945562 |
PubMed | |
| glassman18_panc-nal-iri-5fu-msk_bmcca-29945562 | ||
| Precision medicine and lymphoma Heward JA, et al. Curr Opin Hematol. 2018 Jul;25(4):329-334. PMID: 29738334 |
PubMed | |
| heward18_precision-med-nhl_currophem-29738334 | ||
| Clinical relevance of colorectal cancer molecular subtypes Rodriguez-Salas N, et al. Crit Rev Oncol Hematol. 2017 Jan;109:9-19. Epub 2016 Nov 23. Review. PMID: 28010901 |
PubMed | |
| rodriguez-salas17_colorectal-cms-clinical_critrevonchem-28010901 | ||
| Lynch Syndrome-Associated Colorectal Cancer Sinicrope FA. N Engl J Med. 2018 Aug 23;379(8):764-773. Review. No abstract available. PMID: 30134129 |
PubMed | |
| sincrope18_lynch-colorectal-rev_nejm-30134129 | ||
| August 30, 2018 | Abstracts | |
| Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Bakshi A, et al. Mol Carcinog. 2017 Dec;56(12):2543-2557. Epub 2017 Aug 22. Review. PMID: 28574612 |
PubMed | |
| bakshi17_bcc-hedgehog-beyond_molcarc-28574612 | ||
| Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Chen G, et al. Nature. 2018 Aug;560(7718):382-386. Epub 2018 Aug 8. PMID: 30089911 |
PubMed | |
| chen18_exosomal-pd-l1-immsup_nat-30089911 | ||
| Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Hua J, et al. Onco Targets Ther. 2018 Aug 6;11:4591-4608. eCollection 2018. Review. PMID: 30122951 |
PubMed | |
| hua18_panc-2nd-line-rev_oncotargther-30122951 | ||
| Chimeric Antigen Receptor Therapy June CH, Sadelain M. N Engl J Med. 2018 Jul 5;379(1):64-73. Review. No abstract available. PMID: 29972754 |
PubMed | |
| june18_car-t-review_nejm-29972754 | ||
| Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Kosicki M, et al. Nat Biotechnol. 2018 Sep;36(8):765-771. Epub 2018 Jul 16. PMID: 30010673 |
PubMed | |
| kosicki18_crispr-deletions-rearr_antbiot-30010673 | ||
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Routy B, et al. Science. 2018 Jan 5;359(6371):91-97. Epub 2017 Nov 2. PMID: 29097494 |
PubMed | |
| routy18_gut-microbiome-pd-1-efficacy_sci-29097494 | ||
| August 23, 2018 | Abstracts | |
| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Chalmers ZR, et al. Genome Med. 2017 Apr 19;9(1):34. PMID: 28420421 |
PubMed | |
| chalmers17_100k-genome-mut-burden_genomemed-28420421 | ||
| Frameshift events predict anti-PD-1/L1 response in head and neck cancer. Hanna GJ, et al. JCI Insight. 2018 Feb 22;3(4). pii: 98811. PMID: 29467336 |
PubMed | |
| hanna18_handn-frameshift-pd1-mab_jciinsight-29467336 | ||
| Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. Hussain M, et al. N Engl J Med. 2018 Jun 28;378(26):2465-2474. PMID: 29949494 |
PubMed | |
| hussain18_pca-enza-nonmet-prosper_nejm-29949494 | ||
| Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Levi M, et al. Expert Rev Hematol. 2018 Aug;11(8):663-672. Jul 20. PMID: 29999440 |
PubMed | |
| levi18_dic-update_exprevhem-29999440 | ||
| PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. Migden MR, N Engl J Med. 2018 Jul 26;379(4):341-351. PMID: 29863979 |
PubMed | |
| migden18_cut-sq-ca-pd1-mab_nejm-29863979 | ||
| Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). Shi Q, et al. J Clin Oncol. 2018 Jul 5:JCO2018779124. [Epub ahead of print] PMID: 29975624 |
PubMed | |
| shi18_pfs-os-surrogate-dlbcl_jco-29975624 | ||
| August 12, 2018 | Abstracts | |
| Prediction of acute myeloid leukaemia risk in healthy individuals. Abelson S, et al Nature. 2018 Jul;559(7714):400-404. Epub 2018 Jul 9. PMID: 29988082 |
PubMed | |
| abelson18_predict-aml-risk_nat | ||
| Somatic mutations precede acute myeloid leukemia years before diagnosis. Desai P, et al. Nat Med. 2018 Jul;24(7):1015-1023. Epub 2018 Jul 9. PMID: 29988143 |
PubMed | |
| desai18_mut-precede-aml_natmed | ||
| Microsatellite Instability as a Biomarker for PD-1 Blockade. Dudley JC, et al. Clin Cancer Res. 2016 Feb 15;22(4):813-20. Review. PMID: 26880610 |
PubMed | |
| dudley16_msi-mmr-pd-1-rev_clincanres-26880610 | ||
| Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. Francis PA, et al. SOFT and TEXT Investigators and IBCSG. N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. PMID: 29863451 |
PubMed | |
| francis18_breast-adj-soft-text_nejm | ||
| Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Khoja L, et al. Ann Oncol. 2017 Oct 1;28(10):2377-2385. Review. PMID: 28945858 |
PubMed | |
| khoja17_tumor-class-irae-checkpoint-mab_annonc-28945858 | ||
| A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Thommen DS, et al. Nat Med. 2018 Jun 11. [Epub ahead of print] PMID: 29892065 |
PubMed | |
| thommen18_pd1-cd8-checkpoint-mab_natmed-29892065 | ||
| July 5, 2018 | Abstracts | |
| Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. Brock PR, et al. N Engl J Med. 2018 Jun 21;378(25):2376-2385. PMID: 29924955 |
PubMed | |
| brock18_thiosulfate-cisplatin-hearing_nejm-29924955 | ||
| Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. Grothey A, et al. N Engl J Med. 2018 Mar 29;378(13):1177-1188. PMID: 29590544 |
PubMed | |
| grothey18_duration-adj-crc_nejm-29590544 | ||
| How I treat myeloma with new agents. Moreau P. Blood. 2017 Sep 28;130(13):1507-1513. Epub 2017 Jul 26. Review. PMID: 28747306 |
PubMed | |
| moreau17_how-treat-myeloma_blood-28747306 | ||
| Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nishino M, et al. Nat Rev Clin Oncol. 2017 Nov;14(11):655-668. Epub 2017 Jun 27. Review. PMID: 28653677 |
PubMed | |
| nishino18_monitor-checkpoint-mab_natrevclinonc-28653677 | ||
| The most novel of the novel agents for acute myeloid leukemia. Perl AE. Curr Opin Hematol. 2018 Mar;25(2):81-89. PMID: 29278535 |
PubMed | |
| perl18_novel-agents-aml_curophem-29278535 | ||
| Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis. Semeniuk-Wojtaś A,et al. Clin Genitourin Cancer. 2018 Jun;16(3):e685-e693. Epub 2018 Feb 2. PMID: 29454639 |
PubMed | |
| semeniuk-wojtas18_rcc-biomarkers-meta_clinguca-29454639 | ||
| June 14, 2018 | Abstracts | |
| Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews. Gào X, Schöttker B. Oncotarget. 2017 Apr 16;8(31):51888-51906. eCollection 2017 Aug 1. Review. PMID: 28881698 |
PubMed | |
| gao17_redox-pathways-ca-dev-rev_oncotarg-28881698 | ||
| Breast Cancer in Men. Giordano SH. N Engl J Med. 2018 Jun 14;378(24):2311-2320. No abstract available. PMID: 29897847 |
PubMed | |
| giordano18_breast-ca-men_nejm-29897847 | ||
| Safety of combining radiotherapy with immune-checkpoint inhibition. Hwang WL, et al. Nat Rev Clin Oncol. 2018 Jun 5. [Epub ahead of print] Review. PMID: 29872177 |
PubMed | |
| hwang18_imm-checkpoint-mab-rad_natrevclinonc-29872177 | ||
| In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Smith TT, et al. Nat Nanotechnol. 2017 Aug;12(8):813-820. Epub 2017 Apr 17. PMID: 28416815 |
PubMed | |
| smith17_in-situ-car-t-dna_natnano-28416815 | ||
| The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Swerdlow SH, Blood. 2016 May 19;127(20):2375-90. Epub 2016 Mar 15. Review. PMID: 26980727 |
PubMed | |
| swerdlow16_who-class-hem-malig-lymph_blood-26980727 | ||
| Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial. Wille-Jørgensen P, et al. JAMA. 2018 May 22;319(20):2095-2103. PMID: 29800179 |
PubMed | |
| wille-jorgensen18_colofol-followup-rct_jama-29800179 | ||
| June 5, 2018 | Abstracts | |
| Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. Dimopoulos MA, et al. N Engl J Med. 2018 Jun 1. [Epub ahead of print] PMID: 29856685 |
PubMed | |
| dimopoulos18_ibrut-ritux-waldenstrom_nejm-29856685 | ||
| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. DiNardo CD, et al. N Engl J Med. 2018 Jun 2. [Epub ahead of print] PMID: 29860938 |
PubMed | |
| dinardo18_ivosidenib-idh1-aml_nejm-29860938 | ||
| Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. Francis PA, et al. N Engl J Med. 2018 Jun 4. [Epub ahead of print] PMID: 29863451 |
PubMed | |
| francis18_ov-supression-adj-breast-ca_nejm-29863451 | ||
| Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. Méjean A, et al. N Engl J Med. 2018 Jun 3. [Epub ahead of print] PMID: 29860937 |
PubMed | |
| mejean18_sutent-neph-met-rcc_nejm-29860937 | ||
| Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. Sparano JA, et al. N Engl J Med. 2018 Jun 3. [Epub ahead of print] PMID: 29860917 |
PubMed | |
| sparano18_breast-adj-mid-21-gene_nejm-29860917 | ||
| Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer Zacharakis N, et al. Nature Medicine 2018 Jun 4. doi.org/10.1038/s41591-018-0040-8 |
PubMed | |
| zacharakis18_imm-somatic-mut-breast-ca_natmed | ||
| May 24, 2018 | Abstracts | |
| Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Comoglio PM, Trusolino L, Boccaccio C. Nat Rev Cancer. 2018 Apr 19. [Epub ahead of print] Review. PMID: 29674709 |
PubMed | |
| comoglio18_met-oncogene-therapy_natrevca-29674709 | ||
| STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Hsu JM, et al. Nat Commun. 2018 May 15;9(1):1908. PMID: 29765039 |
PubMed | |
| hsu18_stt3-pd-l1-stem-cell-imm-evasion_natcom-29765039 | ||
| Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Johnson DE, O'Keefe RA, Grandis JR. Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. Epub 2018 Feb 6. Review. PMID: 29405201 |
PubMed | |
| johnson18_jak-stat3-axis-ca_natrevclinonc-29405201 | ||
| IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Padmanabhan A, et al. Chest. 2017 Sep;152(3):478-485. Epub 2017 Apr 17. PMID: 28427966 |
PubMed | |
| padmanabhan17_ivig-hit_chest-28427966 | ||
| Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. Perry JR, et al. N Engl J Med. 2017 Mar 16;376(11):1027-1037. PMID: 28296618 |
PubMed | |
| perry17_gbm-short-rt-tmz_nejm-28296618 | ||
| New Therapies in Head and Neck Cancer. Santuray RT, Johnson DE, Grandis JR. Trends Cancer. 2018 May;4(5):385-396. Epub 2018 Apr 19. Review. PMID: 29709262 |
PubMed | |
| santuray18_new-ther-handn_trendsca-29709262 | ||
| May 18, 2018 | Abstracts | |
| Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Chapuy B, et al Nat Med. 2018 May;24(5):679-690. Epub 2018 Apr 30. PMID: 29713087 |
PubMed | |
| chapuy18_mol-sig-dlbcl_natmed | ||
| Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Frankowski KJ, et al. Sci Transl Med. 2018 May 16;10(441). pii: eaap8307. PMID: 29769289 |
PubMed | |
| frankowski18_metarrestin-arrest-mets_ | ||
| Does nonmetastatic castration-resistant prostate cancer still exist? Higano CS. Nat Rev Clin Oncol. 2018 Apr 23. [Epub ahead of print] No abstract available. PMID: 29686422 |
PubMed | |
| higano18_does-nmcrpc-exist_natrevca | ||
| Revisions to the Tumor, Node, Metastasis staging of lung cancer (8th edition): Rationale, radiologic findings and clinical implications. Kay FU, et al. World J Radiol. 2017 Jun 28;9(6):269-279. Review. PMID: 28717413 |
PubMed | |
| kay17_lung-ajcc8-revisions_wjrad | ||
| Turning Cold Tumors Hot by Blocking TGF-β. Ros XR, Vermeulen L. Trends Cancer. 2018 May;4(5):335-337. Epub 2018 Mar 30. PMID: 29709256 |
PubMed | |
| ros18_turning-cold-ca-hot-tgfb_trendsca | ||
| Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. Schmitz R, et al. N Engl J Med. 2018 Apr 12;378(15):1396-1407. PMID: 29641966 |
PubMed | |
| schmitz18_gene-path-dlbcl_nejm-29641966 | ||
| April 26, 2018 | Abstracts | |
| Pancreatic cancer: yesterday, today and tomorrow. Ansari D, et al. Future Oncol. 2016 Aug;12(16):1929-46. Epub 2016 Jun 1. Review. PMID: 27246628 |
PubMed | |
| ansari18_panc-ca-yes-today-tom_futonc-27246628 | ||
| Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. Bach PB, Saltz LB. J Natl Cancer Inst. 2017 Nov 1;109(11). No abstract available. PMID: 29059436 |
PubMed | |
| bach17_pembro-dosing-cost_jnci-29059436 | ||
| Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Brown M, et al. Science. 2018 Mar 23;359(6382):1408-1411. PMID: 29567714 |
PubMed | |
| brown18_lymph-node-met-route_sci-29567714 | ||
| Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Pereira ER, et al Science. 2018 Mar 23;359(6382):1403-1407. Epub 2018 Mar 22. PMID: 29567713 |
PubMed | |
| pereira18_lymph-node-met-route_sci-29567713 | ||
| Fostamatinib for persistent/chronic adult immune thrombocytopenia. Newland A, et al. Immunotherapy. 2018 Jan;10(1):9-25. Epub 2017 Oct 2. PMID: 28967793 |
PubMed | |
| newland18_fostamatinib-chronic-itp_immther-28967793 | ||
| Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. Tam CS, et al N Engl J Med. 2018 Mar 29;378(13):1211-1223. PMID: 29590547 |
PubMed | |
| tam18_mantle-cell-ibrut-veneto_nejm-29590547 | ||
| Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. Thompson AA, et al. N Engl J Med. 2018 Apr 19;378(16):1479-1493. PMID: 29669226 |
PubMed | |
| thompson18_gene-therapy-beta-thal_nejm-29669226 | ||
| April 17, 2018 | Abstracts | |
| The emerging clinical relevance of genomics in cancer medicine. Berger MF, Mardis ER. Nat Rev Clin Oncol. 2018 Mar 29. [Epub ahead of print] Review. PMID: 29599476 |
PubMed | |
| berger18_clin-rel-gene-ca-med_natrevclinonc-29599476 | ||
| Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. Forde PM, et al. N Engl J Med. 2018 Apr 16. [Epub ahead of print] PMID: 29658848 |
PubMed | |
| forde18_neoadj-pd-1-mab-nsclc_nejm-29658848 | ||
| Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. Gandhi L, et al KEYNOTE-189 Investigators. N Engl J Med. 2018 Apr 16. [Epub ahead of print] PMID: 29658856 |
PubMed | |
| gadhi18_pembro-chemo-nsclc_nejm-29658856 | ||
| Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. Hellmann MD, N Engl J Med. 2018 Apr 16. [Epub ahead of print] PMID: 29658845 |
PubMed | |
| hellmann18_nivo-ipi-nsclc-mut-burden_nejm-29658845 | ||
| Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Lalami Y, Klastersky J. Crit Rev Oncol Hematol. 2017 Dec;120:163-179. Epub 2017 Nov 11. Review. PMID: 29198330 |
PubMed | |
| lalami17_chemo-neutapenia-outcome_critrevonc-29198330 | ||
| Management and Preventive Measures for Febrile Neutropenia. Lucas AJ, Olin JL, Coleman MD. P T. 2018 Apr;43(4):228-232. PMID: 29622943 |
PubMed | |
| lucas18_febrile-neut_pharmther-29622943 | ||
| April 6, 2018 | Abstracts | |
| How I treat double-hit lymphoma. Friedberg JW. Blood. 2017 Aug 3;130(5):590-596. Epub 2017 Jun 9. Review. PMID: 28600333 |
PubMed | |
| friedberg17_how-treat-double-hit-lymph_blood-28600333 | ||
| Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Loibl S, et al. Lancet Oncol. 2018 Apr;19(4):497-509. Epub 2018 Feb 28. PMID: 29501363 |
PubMed | |
| loibl18_brca-parp-brightness_lancetonc-29501363 | ||
| The DNA damage response and cancer therapy. Lord CJ, Ashworth A. Nature. 2012 Jan 18;481(7381):287-94. Review. PMID: 22258607 |
PubMed | |
| lord12_dna-damage-resp-ca-ther_nat-22258607 | ||
| Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Merker JD, et al. J Clin Oncol. 2018 Mar 5:JCO2017768671. [Epub ahead of print] PMID: 29504847 |
PubMed | |
| merker18_circ-tumor-dna-asco-cap_jco-29504847 | ||
| A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine. Ozaki A, et al. Invest New Drugs. 2018 Mar 8. [Epub ahead of print] PMID: 29516231 |
PubMed | |
| ozaki18_transparency-create-x_invnewdrugs-29516231 | ||
| Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Xu LM, et al. Sci Rep. 2017 Aug 23;7(1):9255. PMID: 28835666 |
PubMed | |
| xu17_sclc-es-oligomet-rt_scireps-28835666 | ||
| March 27, 2018 | Abstracts | |
| Porphyria. Bissell DM, et al. N Engl J Med. 2017 Aug 31;377(9):862-872. Review. No abstract available. PMID: 28854095 |
PubMed | |
| bissell17_porphyria_nejm-28854095 | ||
| The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Holch JW, et al. Eur J Cancer. 2017 Jan;70:87-98. Epub 2016 Nov 29. PMID: 27907852 |
PubMed | |
| holch17_colon-ca-location_ejca-27907852 | ||
| Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Lenting PJ, et al. Blood. 2017 Dec 7;130(23):2463-2468. Epub 2017 Oct 17. Review. PMID: 29042366 |
PubMed | |
| lenting17_emicizumab-how-copare_blood-29042366 | ||
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. Motzer RJ, et al. CheckMate 214 Investigators. N Engl J Med. 2018 Mar 21. [Epub ahead of print] PMID: 29562145 |
PubMed | |
| motzer18_nivo-ipi-v-sutent-rcc_nejm-29562145 | ||
| Opportunities and challenges for human papillomavirus vaccination in cancer. Roden RBS, Stern PL. Nat Rev Cancer. 2018 Apr;18(4):240-254. Epub 2018 Mar 2. Review. PMID: 29497146 |
PubMed | |
| roden18_hpv-vac-ca_natrevca-29497146 | ||
| A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. Weber JS, et al. Cancer Immunol Res. 2018 Jan;6(1):79-86. Epub 2017 Dec 5. PMID: 29208646 |
PubMed | |
| weber18_mass-spec-signature-mel-mab_caimmres-29208646 | ||
| March 19, 2018 | Abstracts | |
| DNA methylation-based classification of central nervous system tumours. Capper D, et al. Nature. 2018 Mar 14. [Epub ahead of print] PMID: 29539639 |
PubMed | |
| capper18_dna-meth-class-cns_nat-29539639 | ||
| Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. Gilligan T, et al. J Clin Oncol. 2017 Nov 1;35(31):3618-3632. Epub 2017 Sep 11. Review. PMID: 28892432 |
PubMed | |
| gilligan17_pt-clin-com-skills-asco_jc0-28892432 | ||
| The molecular landscape of head and neck cancer. Leemans CR, et al. Nat Rev Cancer. 2018 Mar 2. [Epub ahead of print] Review. PMID: 29497144 |
PubMed | |
| leemans18_mol-landscape-hnca_natrevca-29497144 | ||
| Myeloproliferative neoplasms: from origins to outcomes. Nangalia J, Green AR. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):470-479. Review. PMID: 29222295 |
PubMed | |
| nangalia17_myeloprolif-origins_hemashedprog-29222295 | ||
| Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Overman MJ, et al. J Clin Oncol. 2018 Mar 10;36(8):773-779. Epub 2018 Jan 20. PMID: 29355075 |
PubMed | |
| overman18_colorec-ipi-nivo-msi_jco-29355075 | ||
| Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Warkentin TE, Pai M, Linkins LA. Blood. 2017 Aug 31;130(9):1104-1113. Epub 2017 Jun 23. Review. PMID: 28646118 |
PubMed | |
| warkentin17_doacs-hit_blood-28646118 | ||
| March 12, 2018 | Abstracts | |
| The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel? Aoun F, et al. Future Oncol. 2017 Dec;13(30):2785-2790. Epub 2017 Nov 30. PMID: 29188727 |
PubMed | |
| aoun17_optimal-rx-hormone-naïve-pca_futonc-29188727 | ||
| How I treat disseminated intravascular coagulation. Levi M, Scully M. Blood. 2018 Feb 22;131(8):845-854. Epub 2017 Dec 18. Review. PMID: 29255070 |
PubMed | |
| levi18_how-treat-dic_blood-29255070 | ||
| PARP inhibitors and breast cancer: highlights and hang-ups. Pettitt SJ, and DJ Lord Exp Rev Precision Med Drug Dev 2018 doi.org/10.1080/23808993.2018.1438187 |
PubMed | |
| pettitt18_parp-inhib-breast-ca_exprevprmeddrugdev | ||
| Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. Schito L, Semenza GL. Trends Cancer. 2016 Dec;2(12):758-770. Epub 2016 Nov 16. Review. PMID: 28741521 |
PubMed | |
| schito16_hif-master-reg-ca_ticancer-28741521 | ||
| Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Stein EM. Future Oncol. 2018 Jan;14(1):23-40. Epub 2017 Sep 18. PMID: 29243965 |
PubMed | |
| stein18_enasidenib_futonc-29243965 | ||
| Diagnosis and classification of hematologic malignancies on the basis of genetics. Taylor J, Xiao W, Abdel-Wahab O. Blood. 2017 Jul 27;130(4):410-423. Epub 2017 Jun 9. Review. PMID: 28600336 |
PubMed | |
| taylor17_dx-class-hem-malig-genetics_blood-28600336 | ||
| March 1, 2018 | Abstracts | |
| Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Brahmer JR, et al. J Clin Oncol. 2018 Feb 14:JCO2017776385. [Epub ahead of print] PMID: 29442540 |
PubMed | |
| brahmer18_mgmt-imm-ae-checkpoint-mabs_jco-29442540 | ||
| Imbalance Between Clinical and Pathologic Staging in the Updated American Joint Commission on Cancer Staging System for Human Papillomavirus-Positive Oropharyngeal Cancer. Fakhry C, Zevallos JP, Eisele DW. J Clin Oncol. 2018 Jan 20;36(3):217-219. Epub 2017 Nov 21. No abstract available. PMID: 29161205 |
PubMed | |
| fakhry17_handn-ajcc-8v7-stage_jco-29161205 | ||
| Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. Hasserjian RP. Curr Opin Hematol. 2018 Mar;25(2):120-128. PMID: 29256927 |
PubMed | |
| hasserjian18_who2016-changes-myeloid_curophem-29256927 | ||
| Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis. Lin RJ, Green DL, Shah GL. Oncologist. 2017 Nov 20. pii: theoncologist.2017-0274. [Epub ahead of print] Review. PMID: 29158366 |
PubMed | |
| lin17_anticoag-brain-ca_theonc-29158366 | ||
| HITs and misses in 100 years of heparin. Rice L. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):667-673. Review. PMID: 29222319 |
PubMed | |
| rice17_hits-misses-heparin_ashedbook-29222319 | ||
| Eosinophils: changing perspectives in health and disease. Rosenberg HF, Dyer KD, Foster PS. Nat Rev Immunol. 2013 Jan;13(1):9-22. Epub 2012 Nov 16. Review. PMID: 23154224 |
PubMed | |
| rosenberg13_eosinophils_natrevimm-23154224 | ||
| Feb 20, 2018 | Abstracts | |
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. DiNardo CD, et al. Lancet Oncol. 2018 Feb;19(2):216-228. Epub 2018 Jan 12. PMID: 29339097 |
PubMed | |
| dinardo18_aml-venetoclax-decitabine_lancetonc | ||
| Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Khan KA, Kerbel RS. Nat Rev Clin Oncol. 2018 Feb 13. [Epub ahead of print] Review. PMID: 29434333 |
PubMed | |
| khan18_immuno-anti-angio_natrevclinonc-29434333 | ||
| Metastatic Prostate Cancer. Sartor O, de Bono JS. N Engl J Med. 2018 Feb 15;378(7):645-657. Epub 2018 Feb 7. No abstract available. PMID: 29412780 |
PubMed | |
| sartor18_met-prostate-ca-rev_nejm-29412780 | ||
| Antiphospholipid syndrome. Schreiber K, et al. Nat Rev Dis Primers. 2018 Jan 25;4:18005. PMID: 29368699 |
PubMed | |
| schreiber18_antiphospholipid_natdisprim-29368699 | ||
| Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. von Minckwitz G, et al. APHINITY Steering Committee and Investigators. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702. PMID: 28581356 |
PubMed | |
| von-minckwitz17_breast-adj-pertuz-trast_nejm-28581356 | ||
| Microsatellite instability: an update. Yamamoto H, Imai K. Arch Toxicol. 2015 Jun;89(6):899-921. Epub 2015 Feb 22. Review. PMID: 25701956 |
PubMed | |
| yamamoto15_msi-update_archtoxi-25701956 | ||
| Feb 12, 2018 | Abstracts | |
| Post-Transplantation Lymphoproliferative Disorders in Adults. Dierickx D, Habermann TM. N Engl J Med. 2018 Feb 8;378(6):549-562. No abstract available. PMID: 29414277 |
PubMed | |
| dierickx18_post-tx-lymph-prolif_nejm | ||
| The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Gaidano G, Rossi D. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):329-337. Review. PMID: 29222275 |
PubMed | |
| gaidano17_cll-mut-landscape_ashedbook | ||
| The bone-marrow niche in MDS and MGUS: implications for AML and MM. Ghobrial IM, et al. Nat Rev Clin Oncol. 2018 Jan 9. [Epub ahead of print] Review. PMID: 29311715 |
PubMed | |
| ghobrial18_bm-mds-mgus-aml-mm-chip_natrevclinonc-29311715 | ||
| Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? Palmieri G, et l. J Transl Med. 2017 Jan 21;15(1):17. PMID: 28109293 |
PubMed | |
| palmieri17_gene-instab-mut-load-immther_jtransmed-28109293 | ||
| Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Smith MR, et ak SPARTAN Investigators. N Engl J Med. 2018 Feb 8. [Epub ahead of print] PMID: 29420164 |
PubMed | |
| smith18_apalutamide-prostate-ca_nejm | ||
| Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. Taphoorn MJB,et al. JAMA Oncol. 2018 Feb 1. [Epub ahead of print] PMID: 29392280 |
PubMed | |
| taphoorn18_gbm-optune-qol_jamaonc | ||
| Feb 5, 2018 | Abstracts | |
| Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Alexandraki KI, et al. Biomed Res Int. 2017;2017:9856140. Epub 2017 Nov 19. Review. PMID: 29349087 |
PubMed | |
| alexandraki17_net-concepts-med-mgmt_biomedresint-29349087 | ||
| What do we know about IDH1/2 mutations so far, and how do we use it? Horbinski C. Acta Neuropathol. 2013 May;125(5):621-36. Epub 2013 Mar 20. Review. PMID: 23512379 |
PubMed | |
| horbinski13_what-know-idh1-mut-use_actanpath-23512379 | ||
| Eradication of spontaneous malignancy by local immunotherapy. Sagiv-Barfi I, ... Levy R. Sci Transl Med. 2018 Jan 31;10(426). pii: eaan4488. PMID: 29386357 |
PubMed | |
| sagiv-barfi18_erad-spont-ca-local-imm_scitranmed | ||
| Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Steensma DP, et al. Blood. 2015 Jul 2;126(1):9-16. Epub 2015 Apr 30. PMID: 25931582 |
PubMed | |
| steensma15_chip-vs-mds_blood-25931582 | ||
| Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. Strosberg J, et al NETTER-1 Trial Investigators. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709 |
PubMed | |
| strosberg17_net-lutitium-dotatate_nejm-28076709 | ||
| Oligodendroglioma: pathology, molecular mechanisms and markers. Wesseling P, et al. Acta Neuropathol. 2015 Jun;129(6):809-27. Epub 2015 May 6. Review. PMID: 25943885 |
PubMed | |
| wesseling15_oligodendroglioma-mol-mech_actanpath-25943885 | ||
| Jan 26, 2018 | Abstracts | |
| Detection and localization of surgically resectable cancers with a multi-analyte blood test. Cohen JD, et al Science. 2018 Jan 18. pii: eaar3247. [Epub ahead of print] PMID: 29348365 |
PubMed | |
| cohen18_multi-ca-screen_science-29348365 | ||
| Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, ... ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. Epub 2017 Dec 10. PMID: 29224502 |
PubMed | |
| connors18_hodgkin-brentux_nejm-29224502 | ||
| Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Moarii M, Papaemmanuil E. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):37-44. Review. PMID: 29222235 |
PubMed | |
| moari17_aml-cytogen-mol-profile_hashedprog-29222235 | ||
| Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Teply BA, et al Lancet Oncol. 2018 Jan;19(1):76-86. Epub 2017 Dec 14. PMID: 29248236 |
PubMed | |
| teply18_pca-bipolar-rx-post-enza_lancetonc-29248236 | ||
| Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. Verdaguer H, et al. J Gastrointest Oncol. 2017 Jun;8(3):405-417. Review. PMID: 28736628 |
PubMed | |
| verdaguer17_biomarkers-gi-ca_jgionc-28736628 | ||
| Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Yaeger R, et al. Cancer Cell. 2018 Jan 8;33(1):125-136.e3. PMID: 29316426 |
PubMed | |
| yaeger18_seq-genomic-met-colorect_cacell-29316426 | ||
| Jan 18, 2018 | Abstracts | |
| How should we sequence and combine novel therapies in CLL? Davids MS. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):346-353. Review. PMID: 29222277 |
PubMed | |
| davids17_seq-combine-novel-cll_hashedprog-29222277 | ||
| Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Neoptolemos JP, et al European Study Group for Pancreatic Cancer. Lancet. 2017 Mar 11;389(10073):1011-1024. Epub 2017 Jan 25. PMID: 28129987 |
PubMed | |
| neoptolemos17_panc-adj-gem-cap-espac4_lancet-28129987 | ||
| Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. Noronha V, et al. J Clin Oncol. 2017 Dec 8:JCO2017749457. [Epub ahead of print] PMID: 29220295 |
PubMed | |
| noronha17_cis-q1-vs-q3-wk-handn_jco-29220295 | ||
| Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. Raskob GE, et al. Cancer Investigators. N Engl J Med. 2017 Dec 12. [Epub ahead of print] PMID: 29231094 |
PubMed | |
| raskob17_edoxaban-ca-thromb_nejm-29231094 | ||
| Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Rini BI, et al Lancet Oncol. 2016 Sep;17(9):1317-24. Epub 2016 Aug 3. PMID: 27498080 |
PubMed | |
| rini16_active-surveil-rcc_lancetonc-27498080 | ||
| Impact of oncogenic pathways on evasion of antitumour immune responses. Spranger S, Gajewski TF. Nat Rev Cancer. 2018 Jan 12. [Epub ahead of print] Review. PMID: 29326431 |
PubMed | |
| spranger18_onc-evade-imm-resp_natrevcan-29326431 | ||
| Jan 2, 2018 | Abstracts | |
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Jones JA, et al. Lancet Oncol. 2017 Dec 12. pii: S1470-2045(17)30909-9. [Epub ahead of print] PMID: 29246803 |
PubMed | |
| jones17_venetoclax-cll-post-ibrutinib_lancetoc-29246803 | ||
| AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. Rangarajan S, et al. N Engl J Med. 2017 Dec 28;377(26):2519-2530. Epub 2017 Dec 9. PMID: 29224506 |
PubMed | |
| rangarajan17_aav-factor8-gene-ther_nejm-29224506 | ||
| Emerging therapies for acute myeloid leukemia. Saygin C, Carraway HE. J Hematol Oncol. 2017 Apr 18;10(1):93. Review. PMID: 28420416 |
PubMed | |
| saygin17_emerging-tx-aml_jhemonc-28420416 | ||
| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC, et all FLAURA Investigators. N Engl J Med. 2017 Nov 18. [Epub ahead of print] PMID: 29151359 |
PubMed | |
| soria17_nsclc-egfr-osimertinib-1st_nejm-29151359 | ||
| The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Tirosh A, Kebebew E. Future Oncol. 2018 Jan;14(2):111-122. Epub 2017 Oct 26. PMID: 29072093 |
PubMed | |
| tirosh17_ga-dotatate-pet-net_futonc-29072093 | ||
| Tumor Mutational Burden and Response Rate to PD-1 Inhibition. Yarchoan M, Hopkins A, Jaffee EM. N Engl J Med. 2017 Dec 21;377(25):2500-2501. No abstract available. PMID: 29262275 |
PubMed | |
| yarchoan17_ras-mut-burden-pd-1_nejm-29262275 | ||
| Dec 19, 2017 | Abstracts | |
| Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. Amzal B, et al. PLoS One. 2017 Sep 8;12(9):e0184423. . eCollection 2017. PMID: 28886175 |
PubMed | |
| amzal17_cabozan-v-all-rcc-meta_plos1-28886175 | ||
| Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Carter PJ, Lazar GA. Nat Rev Drug Discov. 2017 Dec 1.[Epub ahead of print] Review. PMID: 29192287 |
PubMed | |
| carter17_next-gen-ab-drugs-high-fruit_natrevdrugdis-29192287 | ||
| MR imaging and PET/CT in diagnosis and management of multiple myeloma. Ferraro R, Agarwal A, Martin-Macintosh EL, Peller PJ, Subramaniam RM. Radiographics. 2015 Mar-Apr;35(2):438-54. PMID: 25763728 |
PubMed | |
| ferraro15_myeloma-pet-ct-mri_radiographics-25763728 | ||
| The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. Eur J Cancer. 2017 Jan;70:87-98. Epub 2016 Nov 29. PMID: 27907852 |
PubMed | |
| holch17_colorectal-bev-cetux-location_ejcan-27907852 | ||
| Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. Ranieri G, et al. Int J Mol Sci. 2017 Sep 9;18(9). pii: E1937. Review. PMID: 28891933 |
PubMed | |
| ranieri17_tki-rcc-pet-ct_ijmolsci-28891933 | ||
| De-novo and acquired resistance to immune checkpoint targeting. Syn NL, Teng MWL, Mok TSK, Soo RA. Lancet Oncol. 2017 Dec;18(12):e731-e741. Review. PMID: 29208439 |
PubMed | |
| syn17_resistance-imm-checkpoint_lancetonc-29208439 | ||
| Dec 12, 2017 | Abstracts | |
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Arber DA, Blood. 2016 May 19;127(20):2391-405. Epub 2016 Apr 11. Review. PMID: 27069254 |
PubMed | |
| arber16_who-class-hem-malig_blood-27069254 | ||
| Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. George LA, et al. N Engl J Med. 2017 Dec 7;377(23):2215-2227. PMID: 29211678 |
PubMed | |
| george17_hemo-b-gene-tx-trial_nejm-29211678 | ||
| Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Guihot A, et al. Ann Oncol. 2017 Dec 1. [Epub ahead of print] No abstract available. PMID: 29206889 |
PubMed | |
| guihot17_hiv-nivo-nsclc_annonc-29206889 | ||
| Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Hillengass J, et al. Blood Cancer J. 2017 Aug 25;7(8):e599. PMID: 28841211 |
PubMed | |
| hillengass17_myeloma-ct-vs-survey_bloodcaj-28841211 | ||
| Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Khagi Y, et al. Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. PMID: 28972084 |
PubMed | |
| khagi17_hypermut-circ-checkpoint-ab_clincanres-28972084 | ||
| Spurring science, marking progress, and influencing history. Perez-Garcia J Nature Reviews Clinical Oncology 2017/12/12/online http://dx.doi.org/10.1038/nrclinonc.2017.191 |
Abstract | |
| perez-garcia17_breast-ca-2017_natrevclinonc | ||
| Dec 5, 2017 | Abstracts | |
| Chimeric antigen receptor T-cell therapies for lymphoma. Brudno JN, Kochenderfer JN. Nat Rev Clin Oncol. 2017 Aug 31. [Epub ahead of print] Review. PMID: 28857075 |
PubMed | |
| brudno17_car-t-lymphoma_natrevclinonc-28857075 | ||
| Treatment of bone metastases in urologic malignancies. Froehner M, et al. Urol Int. 2014;93(3):249-56. Epub 2014 Aug 7. Review. PMID: 25115989 |
PubMed | |
| froehner14_bone-met-urol-malig_urologia-25115989 | ||
| The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies. Lirov R, Worden FP, Cohen MS. Drugs. 2017 May;77(7):733-745. PMID: 28361210 |
PubMed | |
| lirov17_adv-thyroid-ca-rx_drugs-28361210 | ||
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. Long GV, et al. N Engl J Med. 2017 Nov 9;377(19):1813-1823. Epub 2017 Sep 10. PMID: 28891408 |
PubMed | |
| long17_mel-adj-dab-tram-v600e_nejm-28891408 | ||
| Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Neelapu SS, et al. Nat Rev Clin Oncol. 2017 Sep 19. [Epub ahead of print] Review. PMID: 28925994 |
PubMed | |
| neelapu17_car-t-toxicity-mgmt_natrevclinonc-28925994 | ||
| Adjuvant Melanoma Therapy - Head-Spinning Progress. Schuchter LM. N Engl J Med. 2017 Nov 9;377(19):1888-1890. No abstract available. PMID: 29117487 |
PubMed | |
| schuchter17_adj-mel-head-spin_nejm | ||
| Nov 27, 2017 | Abstracts | |
| Treatment of renal cell carcinoma: Current status and future directions. Barata PC, Rini BI. CA Cancer J Clin. 2017 Nov;67(6):507-524. Epub 2017 Sep 29. Review. PMID: 28961310 |
PubMed | |
| barata17_rcca-treatment-status_cacanjclin-28961310 | ||
| A Mind Map for Managing Minimal Residual Disease in Acute Myeloid Leukemia. Benton DB, Ravandi F. Clin Adv Hem Onc 2017 Nov; 15(11):859 |
Publisher | |
| benton17_mind=map-mrd-aml_clinadhemonc | ||
| Targeting BCL-2 in B-cell lymphomas. Davids MS. Blood. 2017 Aug 31;130(9):1081-1088. Epub 2017 Jul 19. Review. PMID: 28724540 |
PubMed | |
| davids17_target-bcl2-lymphoma_blood-28724540 | ||
| Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. Faries MB, et al. N Engl J Med. 2017 Jun 8;376(23):2211-2222. PMID: 28591523 |
PubMed | |
| faries17_mel-snl-obs_nejm-28591523 | ||
| Lung cancer 2017: Giant steps and stumbling blocks. Heigener DF, Reck M. Nat Rev Clin Oncol. 2017 Nov 21. [Epub ahead of print] PMID: 29158589 |
PubMed | |
| heigener17_lung-ca-2017_natrevclinonc-29158589 | ||
| The molecular underpinnings of prostate cancer: impacts on management and pathology practice. Rodrigues DN, et al. J Pathol. 2017 Jan;241(2):173-182. Epub 2016 Dec 1. Review. PMID: 27753448 |
PubMed | |
| rodrigues17_mol-underpin-prostate-ca_jpath-27753448 | ||
| Nov 15, 2017 | Abstracts | |
| Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Alakel N, et al. Onco Targets Ther. 2017 Feb 2;10:597-605. eCollection 2017. Review. PMID: 28203093 |
PubMed | |
| alakel17_tumor-lysis-syn_oncotargther-28203093 | ||
| Merkel cell carcinoma. Becker JC, et al. Nat Rev Dis Primers. 2017 Oct 26;3:17077. Review. PMID: 29072302 |
PubMed | |
| becker17_merkel-cell_natrevdisprim-29072302 | ||
| Letermovir for the management of cytomegalovirus infection. Bowman LJ, Melaragno JI, Brennan DC. Expert Opin Investig Drugs. 2017 Feb;26(2):235-241. Epub 2016 Dec 28. Review. PMID: 27998189 |
PubMed | |
| bowman17_letermovir-cmv_expopinvdrug-27998189 | ||
| Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. Cheson BD, et al. Oncologist. 2017 Nov;22(11):1283-1291. Epub 2017 Aug 29. Review. PMID: 28851760 |
PubMed | |
| cheson17_tls-targeted-cll_theonc-28851760 | ||
| Small-cell lung cancer: what we know, what we need to know and the path forward. Gazdar AF, Bunn PA, Minna JD. Nat Rev Cancer. 2017 Oct 27. Review. Erratum in: Nat Rev Cancer. 2017 Nov 10;:. PMID: 29077690 |
PubMed | |
| gazdar17_small-cell-lung-know_natrevcan-29077690 | ||
| Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Kulke MH, et al. J Clin Oncol. 2017 Jan;35(1):14-23. Epub 2016 Oct 28. PMID: 27918724 |
PubMed | |
| kulke17_telotristat-ethyl-thi-carcinoid_jco-27918724 | ||
| Nov 8, 2017 | Abstracts | |
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Adalsteinsson VA, et al. Nat Commun. 2017 Nov 6;8(1):1324. PMID: 29109393 |
PubMed | |
| adalsteinsson17_whole-exome-liq-bx_natcom | ||
| A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Ciombor KK, Bekaii-Saab T. Oncologist. 2017 Oct 11. pii: theoncologist.2017-0203. . [Epub ahead of print] Review. PMID: 29021377 |
PubMed | |
| ciombor17_colorec-rx-sequence-29021377 | ||
| Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. Maffioli M, Mora B, Passamonti F. Clin Adv Hematol Oncol. 2017 Sep;15(9):700-707. PMID: 28949941 |
PubMed | |
| maffioli17_pcv-new-dx-tx_clinadvhemonc-28949941 | ||
| Olaratumab for the treatment of soft-tissue sarcoma. Pender A, Jones RL. Future Oncol. 2017 Oct;13(24):2151-2157. doi: 10.2217/fon-2017-0210. Epub 2017 Jul 26. PMID: 28745071 |
PubMed | |
| pender17_olaratumab-st-sarcoma_futonc-28745071 | ||
| Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Sibaud V, et al. Curr Opin Oncol. 2016 Jul;28(4):254-63. Review. PMID: 27136138 |
PubMed | |
| sibaud16_derm-comp-antipd1_curoponc-27136138 | ||
| Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Stoffel NU, et al. Lancet Haematol. 2017 Nov;4(11):e524-e533. (17)30182-5. Epub 2017 Oct 9. PMID: 29032957 |
PubMed | |
| stoffel17_fe-qod-anemia_lancethaem-29032957 | ||
Nov 1, 2017 |
Abstracts | |
| The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists. Burri SH, et al. Am J Clin Oncol. 2017 Aug 24. [Epub ahead of print] PMID: 28832384 |
PubMed | |
| burri17_optune-gbm-guide_ajclinonc-28832384 | ||
| Fertility Preservation in Women. Donnez J, Dolmans MM. N Engl J Med. 2017 Oct 26;377(17):1657-1665. No abstract available. PMID: 29069558 |
PubMed | |
| donnez17_fertility-pres-women_nejm-29069558 | ||
| Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nishino M, et al. Nat Rev Clin Oncol. 2017 Nov;14(11):655-668. 2017.88. Epub 2017 Jun 27. Review. PMID: 28653677 |
PubMed | |
| nishino17_monitor-imm-checkpoint_natrevclinonc-28653677 | ||
| Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. Pollack CV Jr, et al. N Engl J Med. 2017 Aug 3;377(5):431-441. Epub 2017 Jul 11. PMID: 28693366 |
PubMed | |
| pollack17_idarucizumab-dabig-rev_nejm-28693366 | ||
| Cholangiocarcinoma - evolving concepts and therapeutic strategies. Rizvi S, et al. Nat Rev Clin Oncol. 2017 Oct 10. [Epub ahead of print] Review. PMID: 28994423 |
PubMed | |
| rizvi17_cholangio-evolving_natrevclinonc-28994423 | ||
| Understanding and targeting resistance mechanisms in NSCLC. Rotow J, Bivona TG. Nat Rev Cancer. 2017 Oct 25;17(11):637-658. Review. PMID: 29068003 |
PubMed | |
| rotow17_nsclc-resistance_natrevcan-29068003 | ||
| Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. Stupp R, et al. JAMA. 2015 Dec 15;314(23):2535-43. PMID: 26670971 |
PubMed | |
| stupp15_optune-tmz-gbm_jama-26670971 | ||
| Oct 25, 2017 | Abstracts | |
| Anemia in older persons. Bross MH, Soch K, Smith-Knuppel T. Am Fam Physician. 2010 Sep 1;82(5):480-7. PMID: 20822082 |
PubMed | |
| bross10_anemia-older-persons_aafp-20822082 | ||
| Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Dimopoulos MA, et al. Lancet Oncol. 2017 Oct;18(10):1327-1337. (17)30578-8. Epub 2017 Aug 23. PMID: 28843768 |
PubMed | |
| dimopoulos17_carfil-vs-bortez-mm_lancetonc-28843768 | ||
| The NOMS framework: approach to the treatment of spinal metastatic tumors. Laufer I, et al. Oncologist. 2013 Jun;18(6):744-51. Epub 2013 May 24. PMID: 23709750 |
PubMed | |
| laufer17_noms-frame-spinal-mets_theonc-23709750 | ||
| Anticoagulating the subsegmental pulmonary embolism in cancer patients: a survey amongst different medical specialties. Lim WY, et al. J Thromb Thrombolysis. 2015 Jul;40(1):37-41. doi: 10.1007/s11239-014-1143-9. PMID: 25326367 | PubMed | |
| lim15_anticoag-subseg-pe-ca_jthromthrom-25326367 | ||
| Carfilzomib versus bortezomib: no longer an ENDEAVOR. van de Donk NW. Lancet Oncol. 2017 Oct;18(10):1288-1290. Epub 2017 Aug 23. No abstract available. PMID: 28843767 |
PubMed | |
| vandedonk17_carfilz-vs-bortez-mm-comment_lancetonc-28843767 | ||
| New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. Zarrabi K, Fang C, Wu S. J Hematol Oncol. 2017 Feb 2;10(1):38. Review. PMID: 28153029 |
PubMed | |
| zarrabi17_rcca-rx-prior-anti-angio_jhemonc-28153029 | ||
| Oct 18, 2017 | Abstracts | |
| Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. Chu MP, et al. JAMA Oncol. 2017 Jun 1;3(6):767-773. PMID: 27737436 |
PubMed | |
| chu17_ppi-capecitabine-trio_jamaonc-27737436 | ||
| Follicular cell-derived thyroid cancer. Dralle H, et al. Nat Rev Dis Primers. 2015 Dec 10;1:15077. Review. PMID: 27188261 |
PubMed | |
| dralle15_follicular-thyroid-ca_natrevdisprim-27188261 | ||
| Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial Akiko Hanai JNCI J Natl Cancer Inst (2018) 110(2): djx178 |
||
| hanai17_cryo-neuropathy-tax_jnci | ||
| Working Hand in Glove to Prevent Chemotherapy-Induced Peripheral Neuropathy Dawn L. Hershman JNCI J Natl Cancer Inst (2018) 110(2): djx180 |
||
| hershman17_cryo-neuropaty-edit_jnci | ||
| First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. Lemery S, Keegan P, Pazdur R. N Engl J Med. 2017 Oct 12;377(15):1409-1412. PMID: 29020592 |
PubMed | |
| lemery17_fda-approval-agnostic-site_nejm-29020592 | ||
| Gene Therapy in a Patient with Sickle Cell Disease. Badat M, Davies J. N Engl J Med. 2017 May 25;376(21):2093-4. PMID: 28541013 |
PubMed | |
| ribeil17_gene-therapy-sickle_nejm-28249145 | ||
| Oct 11, 2017 | Abstracts | |
| Which Anti-CD20 Antibody Is Better in Follicular Lymphoma? Armitage JO, Longo DL. N Engl J Med. 2017 Oct 5;377(14):1389-1390. No abstract available. PMID: 28976852 |
PubMed | |
| armitage17_which-anti-cd20-fol-lymph_nejm-28976852 | ||
| A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. Birkeland AC, Swiecicki PL, Brenner JC, Shuman AG. Expert Rev Precis Med Drug Dev. 2016;1(4):379-385. Epub 2016 Jul 15. PMID: 28251187 |
PubMed | |
| birkeland17_drugs-in-dev-handn_exprevpmeddrugdev-28251187 | ||
| The VA Point-of-Care Precision Oncology Program: Balancing Access with Rapid Learning in Molecular Cancer Medicine. Fiore LD, Brophy MT, Turek S, Kudesia V, Ramnath N, Shannon C, Ferguson R, Pyarajan S, Fiore MA, Hornberger J, Lavori P. Biomark Cancer. 2016 Feb 29;8:9-16. eCollection 2016. PMID: 26949343 |
PubMed | |
| fiore16_va-precision-onc-maveric_biomarkcan-26949343 | ||
| The evolving role of microsatellite instability in colorectal cancer: A review. Gelsomino F, et al. Cancer Treat Rev. 2016 Dec;51:19-26. Epub 2016 Oct 27. Review. PMID: 27838401 |
PubMed | |
| gelsomino16_msi-colon-ca_catreatrev-27838401 | ||
| Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. Marcus R, et al N Engl J Med. 2017 Oct 5;377(14):1331-1344. PMID: 28976863 |
PubMed | |
| marcus17_obinutuzumab-1st-fol-lymph_nejm-28976863 | ||
| Oct 4, 2017 | Abstracts | |
| Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: Scientifically Relevant or Natural Selection? Biswas B, et al. J Clin Oncol. 2017 Apr 10;35(11):1265-1266. Epub 2017 Feb 6. No abstract available. PMID: 28165897 |
PubMed | |
| biswas17_nephrectomy-tki-ed_jco-28165897 | ||
| Adding radiotherapy to chemotherapy in advanced NSCLC. Brower V. Lancet Oncol. 2017 Sep 28. pii: S1470-2045(17)30771-4. [Epub ahead of print] No abstract available. PMID: 28965744 |
PubMed | |
| brower17_rt-stage-iv-nsclc_lanonc-28965744 | ||
| Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. Hanna N et al. J Clin Oncol. 2016 Sep 20;34(27):3267-75. Epub 2016 Jun 20. PMID:27325852 |
PubMed | |
| hanna16_nephrectomy-tki_jco-27325852 | ||
| Renal cell carcinoma James J. Hsieh et al Nat Rev Dis Primers 3:17009 |
PubMed | |
| hsieh17_renal-cell-ca_natrevdisprim-28276433 | ||
| Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. Iyengar P, et al JAMA Oncol. 2017 Sep 24:e173501. [Epub ahead of print] PubMed PMID: 28973074. |
PubMed | |
| iyengar17_rt-stage-iv-nsclc_jamaonc-28973074 | ||
| Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Knollman H, Godwin JL, Jain R, Wong YN, Plimack ER, Geynisman DM. Ther Adv Urol. 2015 Dec;7(6):312-30. Review. PubMed PMID: 26622317; PubMed Central PMCID: PMC4647143. |
PubMed | |
| knollman15_bladder-systemic-rx-rev_theradvurol-26622317 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Le DT et al N Engl J Med. 2015 Jun 25;372(26):2509-20. Epub 2015 May 30. PMID:26028255 |
PubMed | |
| le15_colorectal-mismatch-checkpoint-mab_nejm-26028255 | ||
| Sept 27, 2017 | Abstracts | |
| Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. Abida W, et al. JCO Precis Oncol. 2017 Jul;2017. Epub 2017 May 31. PMID: 28825054 |
PubMed | |
| abida17_pca-genomic-profile_jcopreonc-28825054 | ||
| Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. Boussiotis VA. N Engl J Med. 2016 Nov 3;375(18):1767-1778. Review. No abstract available. PMID: 27806234 |
PubMed | |
| boussiotis17_pd1-pathway-rev_nejm-27806234 | ||
| Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. Donohoe CL, Reynolds JV. J Thorac Dis. 2017 Jul;9(Suppl 8):S697-S704. Review. PMID: 28815065 |
PubMed | |
| donohoe17_esoph-neoadj-evidence-questions_jthordis-28815065 | ||
| Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored. Li SK, Martin A. Trends Mol Med. 2016 Apr;22(4):274-89. Epub 2016 Mar 9. Review. PMID: 26970951 |
PubMed | |
| li16_mismatch-colon-mech_trendmolmed-26970951 | ||
| Hepatocellular carcinoma. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Nat Rev Dis Primers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18. Review. PMID: 27158749 |
PubMed | |
| llovet17_hcc_natrevdisprim-27158749 | ||
| Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. Reck M, Rabe KF. N Engl J Med. 2017 Aug 31;377(9):849-861.Review. No abstract available. PMID: 28854088 |
PubMed | |
| reck17_nsclc-precision-dx-tx_nejm-28854088 | ||
| Systemic treatment of renal cell cancer: A comprehensive review. Sánchez-Gastaldo A, Kempf E, González Del Alba A, Duran I. Cancer Treat Rev. 2017 Sep 1;60:77-89. doi: 10.1016/j.ctrv.2017.08.010. [Epub ahead of print] Review. PubMed PMID: 28898679. |
PubMed | |
| sanchez-gastaldo17_systemic-renal-cell-ca_catreatrev-28898679 | ||
| Sept 20, 2017 | Abstracts | |
| Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Antonia SJ et al N Engl J Med. 2017 Sep 8. doi: 10.1056/NEJMoa1709937. [Epub ahead of print] PubMed PMID: 28885881. | PubMed | |
| antonia17_nsclc-stage3-durvalumab-post-crt_nejm-28885881 | ||
| Recent Developments in Radiotherapy. Citrin DE. N Engl J Med. 2017 Sep 14;377(11):1065-1075. doi: 10.1056/NEJMra1608986. Review. PubMed PMID: 28902591. |
PubMed | |
| citrin17_recent-dev-radiotherapy_nejm-28902591 | ||
| Prostate cancer: A new standard-of-care for advanced-stage disease. Hamid AA, Sweeney CJ. Nat Rev Clin Oncol. 2017 Oct;14(10):592-593. Epub 2017 Aug 8. PubMed PMID: 28786417. |
PubMed | |
| hamid17_met-prostate-ca-adt-abi-1st_natrevclinonc-28786417 | ||
| Unravelling the biology of SCLC: implications for therapy. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Nat Rev Clin Oncol. 2017 Sep;14(9):549-561. Epub 2017 May 23. Review. PubMed PMID: 28534531. |
PubMed | |
| sabari17_sclc-biology_natrevclinca-28534531 | ||
| Integrating liquid biopsies into the management of cancer. Siravegna G, Marsoni S, Siena S, Bardelli A. Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. Epub 2017 Mar 2. Review. PubMed PMID: 28252003. |
PubMed | |
| siravegna17_liquid-biopsies_natrevclincan-28252003 | ||
| Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. Weber J, et al. N Engl J Med. 2017 Sep 10. [Epub ahead of print] PubMed PMID: 28891423. | PubMed | |
| weber17_adjuvant-nivo-v-ipi-melanoma_nejm-28891423 | ||
The standardized reference naming scheme is explained here.
Kemp B. Cease, MD, MBA